In fact, in preclinical studies using melanoma and colon cancer animal models, tumor cell vaccines expressing GM-CSF and anti-PD1 exhibited profound antitumor T cell responses and improved the overall survival of tumor-bearing mice as compared to mice treated with either GM-CSF or anti-PD-1 alone (194, 195). This evidence concerns the gene PDCD1 and malignant colon neoplasm.